Aspire Biopharma Holdings (ASBP) Change in Account Payables (2022 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Change in Account Payables for 5 consecutive years, with $127589.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Account Payables rose 258.72% year-over-year to $127589.0 in Q2 2026; TTM through Jun 2026 was -$1.4 million, a 170.3% decrease from a year earlier, with the FY2025 full-year figure at -$323776.0, down 135.73% from the prior year.
• Change in Account Payables was $127589.0 for Q2 2026 at Aspire Biopharma Holdings, up from -$139535.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $1.1 million in Q1 2025 and troughed at -$1.3 million in Q3 2025.
• A 5-year average of $44967.4 and a median of $30000.0 in 2022 frame the typical range for Change in Account Payables.
• Across the five-year window, Change in Account Payables jumped 3508.21% in 2024 and plunged 2219.6% in 2025, its largest moves.
• Over 5 years, Change in Account Payables stood at $30000.0 in 2022, then slipped by 9.99% to $27002.0 in 2023, then jumped by 3508.21% to $974289.0 in 2024, then sank by 104.78% to -$46526.0 in 2025, then surged by 374.23% to $127589.0 in 2026.
• The last three Change in Account Payables figures came in at $127589.0 (Q2 2026), -$139535.0 (Q1 2026), and -$46526.0 (Q4 2025), per Business Quant data.